Table 1.
Clinical Characteristic of LLIs' group.
| #Subject | Gender | Age (years) | Major desease | Drug treatments |
|---|---|---|---|---|
| L01 | F | 98 | HT, DM | ARBs, ASA, βB, Gl, Metformin |
| L02 | M | 95 | HT, OP | ARBs ASA, ST |
| L03 | M | 95 | COPD, HHD | ASA, ST, Tiotropium Br |
| L04 | F | 98 | DM, HHD, OP, CV | ASA, LD, Gl, Gl |
| L05 | F | 95 | HT, OP, CV | ASA, ST, ACEis |
| L06 | M | 95 | HT, COPD | ST, ACEis, CCB, Tiotropium Br |
| L07 | F | 95 | HT, DM, OP, CV | ASA, βB, Gl |
| L08 | F | 95 | HT, CV | ACEis |
| L09 | M | 96 | HT | CCB, ACEis |
| L10 | F | 96 | HT, OA | Indapamide |
| L11 | F | 98 | HT, CV | ARBs, ASA, ST, βB |
| L12 | M | 95 | CV | ASA |
| L13 | M | 96 | COPD, HT, HF | ARBs, ASA, βB, LD, Tiotropium Br |
| L14 | M | 96 | HT, DM, CV | ARBs, ST, Gl, Metformin |
| L15 | M | 95 | HT, HHD, CV | LD, CCB |
| L16 | F | 98 | HT, DM | ARBs |
| L17 | F | 99 | OA | Nimesulide |
| L18 | F | 95 | COPD, HHD | CCB, Tiotropium Br |
| L19 | F | 96 | HT, DM | ARBs, Gl, Metformin |
| L20 | F | 100 | HT | ACEis |
| L21 | F | 97 | HHD | ARBs |
| L22 | F | 95 | HT | ASA |
| L23 | F | 96 | HF | Spironolactone, Nitroglycerin |
| L24 | M | 96 | HT | LD |
| L25 | F | 95 | HT | βB |
| L26 | F | 99 | DM, HHD | LD, Metformin |
| L27 | F | 97 | HT, HHD | LD |
| L28 | F | 96 | HHD | ASA |
| L29 | F | 96 | HT, HF | Digoxin |
| L30 | F | 95 | HT | ASA, βB |
| L31 | F | 95 | HT, DM | ASA, βB, Metformin |
| L32 | M | 98 | / | / |
| L33 | F | 96 | HT, COPD | ASA, LD, Tiotropium Br |
| L34 | F | 95 | / | / |
| L35 | F | 95 | HT | CCB, ACEis |
| L36 | F | 98 | DM | Gl |
| L37 | F | 97 | HT | CCB |
| L38 | F | 96 | HT | ARBs, Indapamide |
| L39 | F | 95 | HT, OP, CV | ARBs |
| L40 | M | 96 | HT, CV | ACEis |
| L41 | F | 103 | HT, DM, OP | LD, Metformin |
| L42 | F | 95 | DM, HHD | LD, Gl |
| L43 | F | 98 | OP, CV | ACEis |
| L44 | M | 95 | HHD | CCB |
| L45 | F | 97 | HT | ACEis |
| L46 | M | 95 | HHD, HF | βB, LD |
| L47 | F | 97 | CV | Lorazepam |
| L48 | F | 98 | HT, CV, DM | CCB, Metformin, ACEis |
| L49 | F | 98 | HT, DM | ARBs, ASA |
| L50 | M | 97 | HT | ACEis |
| L51 | M | 96 | HT, HF | ASA, βB |
| L52 | F | 99 | HT | ST |
Major disease: HT, hypertension; DM, diabetes mellitus; COPD, chronic obstructive pulmonary disease; HHD, hypertensive heart disease; OP, osteoporosis; CV, cerebral vasculitis; OA, osteoarthritis; HF, heart failure.
Drug treatments: ARBs, angiotensin II receptor blockers; ST, statin; ASA, acetylsalicylic acid; βB, β beta blockers; LD, loop diuretics; ACEis, angiotensin-converting-enzyme inhibitors; CCB, calcium channel blockers; Gl, glinides.